Boundless Bio Inc (Ticker: BOLD US) is a biotechnology company specializing in developing therapies targeting extrachromosomal DNA (ecDNA), which are double-stranded molecules known to drive cancer genes. Boundless Bio Inc focuses on precision oncology and is leading efforts in ecDNA research with programs such as BBI-335 and BBI-825 currently in phase 1 studies.

The company plans to go public on Nasdaq, listing on March 28, 2024. Boundless Bio Inc aims to sell 6.25 million shares, with a price range of USD 15.00 to 17.00. The offering could raise up to USD 106.25 million, with a greenshoe option of an additional 937.50k shares. The offering is managed by Goldman Sachs (Left Lead), Guggenheim Securities LLC, Leerink Partners LLC, and Piper Sandler & Co.